ArticleCanadian respiratory journal
A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.
Article in Canadian respiratory journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.Influenza and other respiratory viruses · 2016Pooled it
- Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.Clinical pharmacokinetics · 2017Trial
- Effect of an In-Home Palivizumab Administration Program for Children with Medical Complexity.Children (Basel, Switzerland) · 2024Article
- RSV Infection in Refugees and Asylum Seekers: A Systematic Review and Meta-Analysis.Epidemiologia (Basel, Switzerland) · 2024Review
- Prediction of hospital-acquired influenza using machine learning algorithms: a comparative study.BMC infectious diseases · 2024Observational
- Epidemiology of respiratory syncytial virus in a large pediatric hospital in Central Italy and development of a forecasting model to predict the seasonal peak.Italian journal of pediatrics · 2024Article
- Genome-wide study of globally distributed respiratory syncytial virus (RSV) strains implicates diversification utilizing phylodynamics and mutational analysis.Scientific reports · 2023Article
- Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada.Journal of the Pediatric Infectious Diseases Society · 2023Article
- The Impact of Coronavirus Disease 2019 on Viral, Bacterial, and Fungal Respiratory Infections.Clinics in chest medicine · 2023Review
- Review
- RSV disease in infants and young children: Can we see a brighter future?Human vaccines & immunotherapeutics · 2022Article
- Content validation of a caregiver diary to monitor severity and recovery of pediatric patients with respiratory syncytial virus infection.Journal of patient-reported outcomes · 2022Article
- Respiratory Syncytial Virus: Knowledge, Attitudes and Beliefs of General Practitioners from North-Eastern Italy (2021).Pediatric reports · 2022Article
- Association between climatic factors and respiratory syncytial virus detection rates in Cheonan, Korea.Environmental science and pollution research international · 2022Article
- Machine learning early prediction of respiratory syncytial virus in pediatric hospitalized patients.Frontiers in pediatrics · 2022Article
- Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases.Molecular aspects of medicine · 2021Review
- Severe acute respiratory syndrome coronavirus 2 and respiratory syncytial virus coinfection in children.Osong public health and research perspectives · 2021Article
- Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018.BMC infectious diseases · 2021Article
- The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors.EMBO molecular medicine · 2021Article
- Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.Archives of disease in childhood · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a common infection in infancy, with nearly all children affected by two years of age. Approximately 0.5% to 2.0% of all children are hospitalized with lower respiratory tract disease, of which 50% to 90% have bronchiolitis and 5% to 40% have pneumonia. Morbidity and mortality are highest in children with nosocomial infection and in those with underlying medical illnesses such as cardiac and chronic lung disease. Aboriginal children residing in remote northern regions are specifically considered to be at high risk for hospitalization due to RSV infection. Thorough hand washing and health education are the principal strategies in primary prevention. In the absence of a vaccine, palivizumab prophylaxis is currently the best intervention to reduce the burden of illness and RSV-related hospitalization in high-risk children. Health care professionals should provide palivizumab prophylaxis cost effectively in accordance with recommendations issued by pediatric societies and national advisory bodies. The present article reviews the epidemiology of RSV infection and the short- and long-term impact of disease in high-risk infants and special populations. Prevention strategies and treatment are discussed based on the existing scientific evidence, and future challenges in the management of RSV infection are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.